Publications
251
Citations
6,033
Est. group size
~20
Recurring co-author estimate
Active years
48
Publishing since 1979
Michael K. Wendt's research focuses on breast cancer, particularly how cancer cells spread (metastasize) and how they can become dormant and later re-emerge as recurrent tumors. His work examines cell signaling pathways involving growth factor receptors (such as EGFR and FGFR) and explores drug candidates, including a histone deacetylase inhibitor, that might block tumor growth and spread. Much of this research uses preclinical (laboratory and animal) models to test potential cancer therapies.
Publication output was fairly steady (7-14 per year) from 2017-2022, then spiked sharply in 2023 before settling to a still-elevated level in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- High-energy X-ray radiography with apodized petawatt laser beams
Optics Express · 2025
- Prospective video-based analysis of coronal lower limb alignment may be as accurate as radiography in children
BMC Musculoskeletal Disorders · 2025
- Abstract 1365: Histamine from mast cells protects against breast cancer recurrence
Cancer Research · 2025
- Supplementary Data from Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
2023
- Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023
- Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023
- Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023
- Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023
- Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023
- Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023
- Data from Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
2023
- Supplementary Data from Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
2023
- THU485 The Impact Of Cured, Fried Bacon On The Reemergence From Breast Cancer Dormancy
Journal of the Endocrine Society · 2023
- Data from Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
2023
- Receptor tyrosine kinase signaling and targeted therapies
The biomedical & life sciences collection. · 2022
- Cancer Research×20
- bioRxiv (Cold Spring Harbor Laboratory)×8
- UNC Libraries×4
- Cancer & Metabolism×3
- Breast Cancer Research×3
- Emily T. Chan
Medicine · The Ohio State University
- Joe T. Sharick
Medicine · The Ohio State University
- Rebecca Lamb
Medicine · The Ohio State University
- Safa Mohamad
Medicine · Indiana University
- Amanda J. Saraf
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile